Media Release
Prof. Didier Blaise joins Clinical Advisory Board
Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory Board.
Mr Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and
- Posted by: Race Oncology
FeaturedMedia Release
Race raises A$1.8 million, appoints Non-Executive Chairman
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a strategic placement of six million ordinary shares, at an issue price of $0.30 per share.
- Posted by: Race Oncology
Video
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
- Posted by: Race Oncology
Media Release
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019.
- Posted by: Race Oncology
Media Release
Race appoints Australian Clinical Program Director
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director.
- Posted by: Race Oncology
FeaturedMedia Release
Professor Borje Andersson appointed Director of Race
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director.
- Posted by: Race Oncology
FeaturedMedia Release
Prof Borje Andersson to Chair RAC Clinical Advisory Board
Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s Clinical Advisory Board (CAB).
- Posted by: Race Oncology
FeaturedMedia Release
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug, Bisantrene.
- Posted by: Race Oncology